Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy

References

• Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927–41.
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
   PubMed Web of Science ®Google Scholar
• Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future. BJU Int 2012;109:1–12.
   PubMed Web of Science ®Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55:62–75.
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–82.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513–21.
   PubMed Web of Science ®Google Scholar
• VanderWalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 2011;61:139–56.
   Google Scholar
• Beebe-Dimmer JL, Freedland SJ. Androgen deprivation therapy: further confirmation of known harms. BJU Int 2013;111:690–1.
   PubMed Web of Science ®Google Scholar
• Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 2013;111:745–52.
   Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010–18.
   PubMed Web of Science ®Google Scholar
• Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010;95:3–10.
   PubMed Web of Science ®Google Scholar
• Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004;64:128–31.
   PubMed Web of Science ®Google Scholar
• Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006;175:1679–83.
   PubMed Web of Science ®Google Scholar
• Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972–8.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55.
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007;100:749–54.
   PubMed Web of Science ®Google Scholar
• Kaipia A, Riikonen J, Norja H, Huhtala H, Laitinen M. Androgen ablation for low-risk prostate cancer is common among male hip fracture patients. Scand J Urol 2013; Epub ahead of print.
   Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64.
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005–7.
   PubMed Web of Science ®Google Scholar
• Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 2006;7:75–89.
   Google Scholar
• Hoiberg M, Nielsen TL, Wraae K, Abrahamsen B, Hagen C, Andersen M, et al. Population-based reference values for bone mineral density in young men. Osteoporos Int 2007;18:1507–14.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003;92:690–4.
   PubMed Web of Science ®Google Scholar
• Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 2008;15:943–52.
   PubMed Web of Science ®Google Scholar
• DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–17.
   PubMed Web of Science ®Google Scholar
• Leslie WD. Clinical review: Ethnic differences in bone mass – clinical implications. J Clin Endocrinol Metab 2012;97:4329–40.
   PubMed Web of Science ®Google Scholar
• Frost M, Wraae K, Abrahamsen B, Hoiberg M, Hagen C, Andersen M, et al. Osteoporosis and vertebral fractures in men aged 60–74 years. Age Ageing 2012;41:171–7.
   PubMed Web of Science ®Google Scholar
• Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802–22.
   PubMed Web of Science ®Google Scholar
• Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 2013;111:1301–9.
   Google Scholar
• Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892–9.
   PubMed Web of Science ®Google Scholar
• Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177:17–24.
   PubMed Web of Science ®Google Scholar
• Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272–82.
   PubMed Web of Science ®Google Scholar